A combined approach of structure-based virtual screening and NMR to interrupt the PD-1/PD-L1 axis: Biphenyl-benzimidazole containing compounds as novel PD-L1 inhibitors.
Donati G, Viviano M, D'Amore VM, Cipriano A, Diakogiannaki I, Amato J, Tomassi S, Brancaccio D, Russomanno P, Di Leva FS, Arosio D, Seneci P, Taliani S, Magiera-Mularz K, Musielak B, Skalniak L, Holak TA, Castellano S, La Pietra V, Marinelli L.
Donati G, et al. Among authors: viviano m.
Arch Pharm (Weinheim). 2024 Mar;357(3):e2300583. doi: 10.1002/ardp.202300583. Epub 2023 Dec 18.
Arch Pharm (Weinheim). 2024.
PMID: 38110703
Free article.